Get started
Author

Richard T. Hauch

Observed names: Hauch, Richard T., Hauch, Richard Tilman, R Hauch, R. Hauch, R.T. Hauch, Richard Hauch
Observed institutions: Universität Hamburg, TUM Klinikum, Queen Fabiola Children's University Hospital, University Medical Center Hamburg-Eppendorf, Kinderkrebs-Zentrum Hamburg, University Cancer Center Hamburg, Technical University of Munich
ORCID: 0000-0002-1282-4803
Observed ORCID: 0000-0002-1282-4803
OpenAlex ID: A5061339000
Venetoclax with azacitidine targets refractory MDS but spares healthy hematopoiesis at tailored dose
2019 · Stefanie Jilg, Richard T. Hauch, et al. · Experimental Hematology and Oncology · 41
PDF
Selective inhibition of BCL-2 is a promising target in patients with high-risk myelodysplastic syndromes and adverse mutational profile
2018 · Veronika Reidel, Johanna Kauschinger, et al. · Oncotarget · 23
PDF
Inhibition of PLK1 by capped‐dose volasertib exerts substantial efficacy in MDS and sAML while sparing healthy haematopoiesis
2019 · Veronika Dill, Johanna Kauschinger, et al. · European Journal Of Haematology · 7
PDF
Combination of 5-Azacytidine and ABT-199 Has a Synergistic Apoptotic Effect in High-Risk MDS/sAML after HMA Failure
2016 · Stefanie Jilg, Johanna Kauschinger, et al. · Blood · 5
Comprehensive characterization of central BCL-2 family members in aberrant eosinophils and their impact on therapeutic strategies
2021 · Timo O. Odinius, Lars Buschhorn, et al. · Journal of Cancer Research and Clinical Oncology · 4
PDF
Abdominal Aspergillosis – an Underdiagnosed Disease? Three Cases of Abdominal Aspergillosis in Severely Immunocompromised Infants
2024 · Richard Hauch, Martin Jankofsky, et al. · Klinische Pädiatrie · 2
Memory-like Natural Killer Cell and CD19 Antibody–Based Immunotherapy in Combination with Tyrosine Kinase Inhibition Has Antitumor Effects against Ph(-like) Acute Lymphoblastic Leukemia
2025 · Zoya Eskandarian, Richard Hauch, et al. · Cancer Immunology Research · 1
A case report of a pediatric T-cell acute lymphoblastic leukemia with a subclonal GCC2::PDGFRB t(2;5) translocation – implementation for the selection of MRD-targets
2025 · Esther L. Monsees, Richard T. Hauch, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 1
Impact of COVID-19 Related Restrictions on Infections in Children with Cancer or after Hematopoietic SCT
2023 · Richard Hauch, Malena Hinrichs, et al. · Klinische Pädiatrie · 1
Characterization of a PRKCE::ETV6 fusion as a potential oncogenic driver in T-cell acute lymphoblastic leukemia
2025 · Esther L. Monsees, Udo zur Stadt, et al. · Molecular and Cellular Pediatrics
PDF
Data from Memory-like Natural Killer Cell and CD19 Antibody–Based Immunotherapy in Combination with Tyrosine Kinase Inhibition Has Antitumor Effects against Ph(-like) Acute Lymphoblastic Leukemia
2025 · Zoya Eskandarian, Richard Hauch, et al.
Figure S12 from Memory-like Natural Killer Cell and CD19 Antibody–Based Immunotherapy in Combination with Tyrosine Kinase Inhibition Has Antitumor Effects against Ph(-like) Acute Lymphoblastic Leukemia
2025 · Zoya Eskandarian, Richard Hauch, et al.
Figure S11 from Memory-like Natural Killer Cell and CD19 Antibody–Based Immunotherapy in Combination with Tyrosine Kinase Inhibition Has Antitumor Effects against Ph(-like) Acute Lymphoblastic Leukemia
2025 · Zoya Eskandarian, Richard Hauch, et al.
Figure S1 from Memory-like Natural Killer Cell and CD19 Antibody–Based Immunotherapy in Combination with Tyrosine Kinase Inhibition Has Antitumor Effects against Ph(-like) Acute Lymphoblastic Leukemia
2025 · Zoya Eskandarian, Richard Hauch, et al.
Figure S4 from Memory-like Natural Killer Cell and CD19 Antibody–Based Immunotherapy in Combination with Tyrosine Kinase Inhibition Has Antitumor Effects against Ph(-like) Acute Lymphoblastic Leukemia
2025 · Zoya Eskandarian, Richard Hauch, et al.
Figure S3 from Memory-like Natural Killer Cell and CD19 Antibody–Based Immunotherapy in Combination with Tyrosine Kinase Inhibition Has Antitumor Effects against Ph(-like) Acute Lymphoblastic Leukemia
2025 · Zoya Eskandarian, Richard Hauch, et al.
Figure S5 from Memory-like Natural Killer Cell and CD19 Antibody–Based Immunotherapy in Combination with Tyrosine Kinase Inhibition Has Antitumor Effects against Ph(-like) Acute Lymphoblastic Leukemia
2025 · Zoya Eskandarian, Richard Hauch, et al.
Figure S6 from Memory-like Natural Killer Cell and CD19 Antibody–Based Immunotherapy in Combination with Tyrosine Kinase Inhibition Has Antitumor Effects against Ph(-like) Acute Lymphoblastic Leukemia
2025 · Zoya Eskandarian, Richard Hauch, et al.
Figure S9 from Memory-like Natural Killer Cell and CD19 Antibody–Based Immunotherapy in Combination with Tyrosine Kinase Inhibition Has Antitumor Effects against Ph(-like) Acute Lymphoblastic Leukemia
2025 · Zoya Eskandarian, Richard Hauch, et al.
Table S2 from Memory-like Natural Killer Cell and CD19 Antibody–Based Immunotherapy in Combination with Tyrosine Kinase Inhibition Has Antitumor Effects against Ph(-like) Acute Lymphoblastic Leukemia
2025 · Zoya Eskandarian, Richard Hauch, et al.
Table S3 from Memory-like Natural Killer Cell and CD19 Antibody–Based Immunotherapy in Combination with Tyrosine Kinase Inhibition Has Antitumor Effects against Ph(-like) Acute Lymphoblastic Leukemia
2025 · Zoya Eskandarian, Richard Hauch, et al.
Table S1 from Memory-like Natural Killer Cell and CD19 Antibody–Based Immunotherapy in Combination with Tyrosine Kinase Inhibition Has Antitumor Effects against Ph(-like) Acute Lymphoblastic Leukemia
2025 · Zoya Eskandarian, Richard Hauch, et al.
Figure S8 from Memory-like Natural Killer Cell and CD19 Antibody–Based Immunotherapy in Combination with Tyrosine Kinase Inhibition Has Antitumor Effects against Ph(-like) Acute Lymphoblastic Leukemia
2025 · Zoya Eskandarian, Richard Hauch, et al.
Figure S7 from Memory-like Natural Killer Cell and CD19 Antibody–Based Immunotherapy in Combination with Tyrosine Kinase Inhibition Has Antitumor Effects against Ph(-like) Acute Lymphoblastic Leukemia
2025 · Zoya Eskandarian, Richard Hauch, et al.
Figure S2 from Memory-like Natural Killer Cell and CD19 Antibody–Based Immunotherapy in Combination with Tyrosine Kinase Inhibition Has Antitumor Effects against Ph(-like) Acute Lymphoblastic Leukemia
2025 · Zoya Eskandarian, Richard Hauch, et al.
Works count: 39
Citation count: 85
H-index: 4
I10-index: 2
Year
Topic
Type